SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-08-05
👔
First Tracks Biotherapeutics, Inc.
@TRAX_InsiderForm 4 Filing: Lizzul Paul F. Acquires (Grant) shares of $TRAX
STOCK AWARD / GRANT
⚡ MATERIALITY: 1/10
corporate issuer
First Tracks Biotherapeutics, Inc.
Ticker: $TRAX
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-08-02
Shares: 60,492
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Lizzul Paul F., holds the title of Chief Medical Officer at First Tracks Biotherapeutics, Inc..
On 2026-08-02, the insider transacted 60,492 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Lizzul Paul F. (Chief Medical Officer) was granted $0 of $TRAX
Post-Transaction Position: 77,159 shares
SEC Accession No: 0001711462-26-000011 (CIK: 1711462)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.